Allarity Therapeutics
Open
$1.37
Prev. Close
$1.37
High
$1.37
Low
$1.36
Market Snapshot
$21.82M
-1.9
-13.02
7
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
emptyResult
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Recently from Cashu
Allarity Therapeutics Under SEC Investigation Following Wells Notice Over Regulatory Compliance Issues
Allarity Therapeutics Faces Regulatory Scrutiny Following SEC Wells Notice Allarity Therapeutics, Inc. is currently under investigation by The Schall Law Firm, which represents investors concerned abo…
Allarity Therapeutics Faces SEC Investigation Over Regulatory Compliance and Disclosure Issues
Regulatory Scrutiny Intensifies for Allarity Therapeutics Amid SEC Investigation Allarity Therapeutics, Inc. faces significant scrutiny following the receipt of a "Wells Notice" from the U.S. Securiti…
Allarity Therapeutics Under Investigation for Potential Securities Law Violations and Regulatory Compliance Issues
Investigation into Allarity Therapeutics Raises Concerns Over Regulatory Compliance Allarity Therapeutics, Inc., a biopharmaceutical company focused on developing cancer therapies, finds itself under…
Allarity Therapeutics Under SEC Investigation for Potential Securities Violations and Misleading Investors
Allarity Therapeutics Faces Legal Scrutiny Over SEC Violations Allarity Therapeutics, Inc. is currently under investigation by the Schall Law Firm for potential violations of securities laws. This inq…